• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

3.880 +0.280 (+7.78%)
Streaming Delayed Price Updated: 1:33 PM EDT, Mar 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prelude Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
July 09, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22 ↗
June 22, 2024
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024. 
Via Talk Markets
News headline image
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
June 03, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Morgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To Know ↗
December 19, 2023
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Prelude Therapeutics ↗
October 19, 2023
 
Via Benzinga
News headline image
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
May 09, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
PRLD Stock Earnings: Prelude Therapeutics Beats EPS for Q1 2024 ↗
May 07, 2024
PRLD stock results show that Prelude Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
April 09, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
March 05, 2024
Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitor 
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
February 29, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
February 16, 2024
 
Via Benzinga
News headline image
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
February 15, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
AI Meets Biotech: 3 Top Stocks Transforming Medical Science ↗
December 16, 2023
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Prelude Therapeutics Announces $25 Million Private Placement
December 11, 2023
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
November 01, 2023
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023
Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader 
From Prelude Therapeutics, Inc.; AbCellera
Via GlobeNewswire
News headline image
Best Buy To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday ↗
October 19, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
October 14, 2023
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
August 29, 2023
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
September 15, 2023
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
August 23, 2023
  Wednesday's session saw 150 companies set new 52-week lows. 
Via Benzinga
News headline image
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 03, 2023
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
July 31, 2023
  On Monday, 27 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
July 27, 2023
  During Thursday, 56 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
July 28, 2023
  Friday's session saw 59 companies set new 52-week lows. 
Via Benzinga
News headline image
Prelude Therapeutics To Participate in Jefferies Healthcare Conference
May 31, 2023
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
May 25, 2023
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap